Hengrui Q3 net profit surges 89%, beats estimates on innovative drug sales

Jiangsu Hengrui Pharmaceuticals reported Q3 net profit of 2.46 billion yuan, up 88.92% year-on-year, beating consensus of 2.38 billion yuan, with revenue up 20.55% to 8.95 billion yuan, also above estimates. The beat is driven by stronger innovative drug sales and out-licensing revenue, signaling continued momentum in China's pharma sector. This is a company-specific earnings beat, not a macro signal, but it may support sentiment for Chinese healthcare equities.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works